Biogen
explores sale of
hemophilia assets: sources
(Reuters) -
Biogen Inc, one of the world's largest biotech**logy companies, is exploring a
sale of its
hemophilia treatments, as it increases its focus on core therapeutic areas, according to people familiar with the matter.
[IMG]http://feeds.feedburner.com/~ff/reuters/healthNews?i=Oip9373vA**:RjcTu_4VIPY:F7zBnMyn0Lo[/IMG] [IMG]http://feeds.feedburner.com/~ff/reuters/healthNews?i=Oip9373vA**:RjcTu_4VIPY:V_sGLiPBpWU[/IMG]
[IMG]http://feeds.feedburner.com/~r/reuters/healthNews/~4/Oip9373vA**[/IMG]
04-08-2016, 11:21 PM
Biogen explores sale of hemophilia assets: sources
العرض الشجري